Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...
Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their ...
Pharmaceutical Technology on MSN6d
Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drugNovo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an ...
Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and ...
Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...
Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential ...
Novo Nordisk has been on the hunt for differentiated ... a drug discovered and developed by Lexicon Pharmaceuticals, the companies announced Friday. LX9851 is an oral small molecule that blocks ...
Lexicon Pharmaceuticals Inc. said March 28 it will exclusively license its drug candidate LX9851 to Danish pharmaceutical ...
Under terms of the deal, Novo Nordisk will obtain global rights to develop, manufacture, and commercialize LX9851 for obesity ...
Investor's Business Daily on MSN6d
Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1Novo Nordisk stock slipped 1.2% to 69.30. Novo Nordisk Is On A Licensing Spree. This is the second big weight-loss deal from Novo ...
Novo inks $1B biobucks Lexicon obesity deal after seeing preclinical prospect shine with semaglutide
Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback